A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

Completed · Phase 3 · Has a placebo group

Conditions studied: Primary Immune Thrombocytopenia

In brief

This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in participants with primary ITP.

Key facts

Study ID

NCT04188379

Run by

argenx

People needed

131

Starts

2019-12-16

Expected to finish

2022-02-03

Last updated by the study team

2025-03-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to understand the requirements of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits).
• Male or female patient aged ≥18 years.
• Confirmed ITP diagnosis, at least 3 months before randomization and according to the American Society of Hematology Criteria, and no known other etiology for thrombocytopenia.
• Diagnosis supported by a response to a prior ITP therapy (other than thrombopoietin receptor agonists [TPO-RAs]), in the opinion of the investigator.
• Mean platelet count of <30×10E9/L from 2 counts: 1 platelet count collected during the screening period and the predose platelet count on the day of randomization.
• At the start of the trial, the patient is either on concurrent ITP treatment(s) and has received at least 1 prior therapy for ITP in the past, or the patient is not on treatment for ITP but has received at least 2 prior treatments for ITP. Patients receiving permitted concurrent ITP treatment(s) at baseline, must have been stable in dose and frequency for at least 4 weeks prior to randomization.
• Women of childbearing potential must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at baseline before trial medication (infusion) can be administered.
• Women of childbearing potential should use a highly effective or acceptable method of contraception during the trial and for 90 days after the last administration of the IMP.

You may not qualify if…

• ITP/thrombocytopenia associated with another condition, eg, lymphoma, chronic lymphocytic leukemia, viral infection, hepatitis, induced or alloimmune thrombocytopenia, or thrombocytopenia associated with myeloid dysplasia.
• Use of certain medications before the start of the studies (more details in the protocol)
• Patients who have a history of malignancy, including malignant thymoma, or myeloproliferative or lymphoproliferative disorders, unless deemed cured by adequate treatment with no evidence of recurrence for ≥3 years before screening. Patients with completely excised non-melanoma skin cancer (such as basal cell carcinoma or squamous cell carcinoma) or cervical carcinoma in situ would be permitted at any time.
• Uncontrolled hypertension, defined as a repeated elevated blood pressure exceeding 160 mmHg (systolic) and/or 100 mmHg (diastolic) despite appropriate treatments.
• History of any major thrombotic or embolic event within 12 months prior to randomization.
• History of coagulopathy or hereditary thrombocytopenia or a family history of thrombocytopenia.
• History of a recent or planned major surgery (that involves major organs eg, brain, heart, lung, liver, bladder, or gastrointestinal tract) within 4 weeks of randomization.
• Positive serum test at screening for an active viral infection with any of the following conditions: Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human immunodeficiency virus (HIV)
• Clinical evidence of significant unstable or uncontrolled acute or chronic diseases other than ITPdespite appropriate treatments which could put the patient at undue risk.
• Patients with known medical history of hypersensitivity to any of the ingredients of the IMP.
• Patients who previously participated in a clinical trial with efgartigimod and have received at least 1 administration of the IMP.
• Pregnant or lactating females. More details in the protocol

Where it is running

• Investigator Site 0010045 — Washington D.C., District of Columbia, United States
• Investigator Site 0010034 — Jacksonville, Florida, United States
• Investigator site 0010037 — Ocala, Florida, United States
• Investigator Site 0010042 — Iowa City, Iowa, United States
• Investigator Site 0010046 — Greenville, North Carolina, United States
• Investigator Site 0010049 — Cleveland, Ohio, United States
• Investigator Site 0010040 — Columbus, Ohio, United States
• Investigator Site 0010041 — Philadelphia, Pennsylvania, United States
• Investigator Site 0430004 — Linz, Austria
• Investigator Site 0430002 — Vienna, Austria
• Investigator Site 0430003 — Vienna, Austria
• Investigator Site 0320012 — Brasschaat, Belgium
• Investigator Site 0320011 — Bruges, Belgium
• Investigator Site 0320015 — Leuven, Belgium
• Investigator Site 0320014 — Turnhout, Belgium
• Investigator Site 0320020 — Verviers, Belgium
• Investigator site 0320002 — Yvoir, Belgium
• Investigator Site 3590001 — Pleven, Bulgaria
• Investigator Site 3590002 — Sofia, Bulgaria
• Investigator Site 4200001 — Brno, Czechia
• Investigator Site 4200008 — Olomouc, Czechia
• Investigator Site 4200006 — Ostrava, Czechia
• Investigator Site 4200007 — Prague, Czechia
• Investigator Site 0330019 — Clermont-Ferrand, France
• Investigator Site 0010038 — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.